CD274 and hepatocellular carcinoma: In order to further evaluate pembrolizumab plus lenvatinib with or without transarterial chemoembolization (TACE) for the treatment of unresectable HCC, Chen et al. retrospectively reviewed a large patient collective, and concluded that the promising combination of pembrolizumab plus lenvatinib with TACE is associated with a controllable safety profile, longer survival time, as well as a higher rate of conversion therapy in programmed death-ligand 1 (PD-L1)-positive, treatment-naïve unresectable HCC [38,39].